The 150-year-old drugmaker is the first company in health care to hit the milestone.
Category: Drugs (Pharmaceuticals)
-
A Pill for Women’s Libido Meets a Cultural Moment
A decade ago, Cindy Eckert struggled to convince skeptics about a drug for premenopausal women. Lately, her business is booming.
-
F.D.A. Sharply Limits Use of Drug Linked to Two Teen Deaths
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Sharon Camp, Mother of the ‘Plan B’ Contraceptive Pill, Dies at 83
An advocate for women’s reproductive health, she started one of the world’s smallest pharmaceutical companies to bring an emergency birth-control method to market.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
-
The Workers Left Out of Trump’s Drug-Manufacturing Renaissance
President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines.
-
F.D.A. Drug Unit Chief Is Placed on Leave, and Cites a ‘Toxic’ Environment
The official, Dr. George F. Tidmarsh, a top regulator at the agency, said disagreements over a new program to rapidly approve medications had caused tensions with agency officials.
-
Why Medicare Recipients Should Check Their 2026 Drug Plans Now
Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them.
-
F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.